Project Grant K08CA279772
Award Date
8/16/24
Completion Date
7/31/29
Dollars Obligated
$293K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a large-scale, multi-site randomized trial to evaluate the efficacy of a targeted palliative care intervention called TARGET-PC for patients with metastatic breast cancer (MBC) who are at high risk of death within 12 months. The $858,166 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will support the enrollment of 400 MBC...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research on improving the safety and efficacy of chemoradiotherapy for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The key products/services to be delivered include: Evaluating how fractionated radiation affects the tumor microenvironment and impacts passive drug delivery, using in vivo imaging, microscopy, and...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $591,372 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a multi-site randomized controlled trial of a novel digital application (DREAMLAND) to improve quality of life and psychological outcomes for patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy. The study will evaluate the efficacy of the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The overarching goal is to generate continuously renewing "HSC CAR-NK cell factories" that can provide long-term, cancer-specific immunity. Specifically, the...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $293,053 to The General Hospital Corporation (Massachusetts General Hospital) to refine and pilot test a psychosocial intervention incorporating Acceptance and Commitment Therapy to address the unmet supportive care needs of patients with primary malignant central nervous system tumors. The 5-year project aims to 1) refine the population-specific intervention,...
This federal Project Grant award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) program, supports a randomized controlled trial to assess the efficacy of a phone-delivered positive psychological intervention (PATH) for improving anxiety, depression, and quality of life in hematopoietic stem cell transplantation (HSCT) survivors. The total award amount is $746,926, with a project period from July 2024 to June 2029. The...
This $780,389 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) is supporting research to develop novel immunotherapies for acute myeloid leukemia (AML). The project aims to use state-of-the-art genetic engineering tools to generate "stealth" versions of key AML target genes, like FLT3, KIT, and IL3RA, that are resistant to CAR-T cell and monoclonal antibody therapies. This approach is intended to allow targeting of...
The National Cancer Institute (NCI) awarded a $251,519 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop, refine, and pilot-test a nurse-led coping and supportive care intervention for patients with triple-negative breast cancer (TNBC) during the transition from curative therapy to surveillance. The 5-year project aims to (1) develop and refine the intervention based on preliminary data...
The National Cancer Institute awarded a $652,725 Project Grant (CFDA 93.395 Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of novel CAR T-cell therapy for treating glioblastoma, a deadly brain cancer. The award supports the development and testing of "CARV3.TEAM-E" cells - engineered CAR T-cells that secrete a T-cell engaging antibody to target both the EGFRVIII and EGFR...
This federal Project Grant award, valued at $176,040, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The award will fund research by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the impact of aging on conventional type 1 dendritic cells (cDC1s) and their influence on CD8+ T cell immunity in the tumor microenvironment of older cancer patients, particularly those with...